Basel/Zurich – Roche, the University of Zurich (UZH), and the University Hospital Zurich (USZ) aim to collaborate on the utilization of routinely collected health data. The Initiative begins with data from cancer patients.
Roche, the University of Zurich (UZH), and the University Hospital Zurich (USZ) have entered into a research agreement, as announced by the Basel-based pharmaceutical company in a statement. Together, the three partner organizations aim to investigate how routinely collected health data can be integrated into clinical routine practices. The goal is to "create an ecosystem for health data," in which these so-called Real World Data (RWD) "can be exchanged securely, transparently, and in compliance with legal frameworks," states Roche.
The beginning is made with the use of data from cancer patients. A corresponding project in the form of a public-private partnership is being developed and co-financed by the three project participants under the name Precision Oncology Program . The ethics committee of the Canton of Zurich has already given its approval, according to the press release.
"Cancer is a very heterogeneous disease," states Prof. Dr. Andreas Wicki, Director of the Clinical Program of the Comprehensive Cancer Center Zurich, as quoted in the press release. "The structured and comprehensive collection of Real World Data (RWD), as in the Precision Oncology Program, can, in the long term, help to better treat patients because we have more information about very specific clinical situations." Dr. Katharina Gasser, General Manager of Roche Pharma Switzerland, is confident "that this project will not only bring meaningful insights for the participating partners and patients but also for the overall Swiss healthcare system." ce/hs